Akari Therapeutics Plc recorded a cumulative net loss of $-28 million during 12 month ending in the first quarter 2026. The Healthcare sector has seen employees of 394 other companies achieving higher income per employee. While Akari Therapeutics Plc's total ranking has deteriorated compared to the previous quarter from 3355 to 3950.
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
In a recent turn of events, Akari Therapeutics, a leading biopharmaceutical company, has appointed esteemed medical professional, Dr. Samir R. Patel, as its Interim CEO. This strategic move is believed to further strengthen the companyns vision and amplify its commitment towards achieving exceptional healthcare outcomes for patients worldwide. Dr. Samir R. Patel, renowned for his wealth of knowledge and expertise in the healthcare industry, has been a significant contributor to Akari Therapeuticsn success over the years. As a member of the board and an active shareholder, Dr. Patel has consistently displayed unwavering dedication towards advancing medical research and ensuring the delivery of groundbreaking therapies.
Akari Therapeutics Plc Secures $7.6 Million in Successful Initial Closing of Private Placement Financing Round In recent news, Akari Therapeutics Plc, a biotechnology company focusing on therapies for autoimmune and inflammatory diseases, has announced the successful initial closing of a private placement financing round. The transaction is projected to raise approximately $7.6 million in gross proceeds from both new and existing investors. It is worth noting that despite this positive development, Akari Therapeutics Plc has recorded a cumulative net loss of $-18 million during the 12 months ending in the fourth quarter of 2022. Additionally, the company s overall ranking has declined compared to the third quarter of 2022, falling from 0 to 3265.
Akari Therapeutics Announces $2 Million Private Placement Financing with Existing Investors Boston and London, Jan. 02, 2024 - Akari Therapeutics, a leading biotechnology company focused on advanced therapies for autoimmune and inflammatory diseases, announced today the successful completion of a private placement financing with existing investors. The financing, which closed on December 29, 2023, raised approximately $2 million in gross proceeds for the company. The private placement involved the participation of Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., demonstrating their continued support and confidence in the company s mission and potential. This influx of capital will provide Akari Therapeutics with additional resources to advance its late-stage biotechnology research and development efforts.
Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
